Testicular Microlithiasis: Clinical Significance and Management
Testicular microlithiasis (TML) is a benign imaging finding that, when isolated and without additional risk factors, does not increase cancer risk and requires no follow-up or further evaluation. 1
Understanding the Clinical Context
TML appears on ultrasound as multiple small (1-3 mm) hyperechoic foci scattered throughout the testicular parenchyma, representing calcifications within seminiferous tubules. While historically concerning, the most recent high-quality guidelines from the ACR (2022) and EAU (2023) have clarified its benign nature in most cases.
Key Evidence on Cancer Risk
The relationship between TML and testicular cancer has been definitively clarified:
- TML occurs in 5.6% of healthy young men 2, while testicular cancer develops in only 3-5 per 100,000 men—a 1,000-fold difference
- Isolated TML without other risk factors does not confer increased malignancy risk 1
- TML only becomes clinically significant when accompanied by established testicular cancer risk factors 1, 3
This represents a critical shift from older literature that suggested routine surveillance for all TML cases.
Management Algorithm
For Isolated TML (No Risk Factors Present):
- No follow-up imaging required 1, 3
- No biopsy indicated 3
- Reassure the patient this is a benign incidental finding
- Educate on testicular self-examination
For TML with Additional Risk Factors:
- Annual ultrasound surveillance until age 55 3
- Consider individual risk stratification based on specific factors present
Risk Factors Requiring Surveillance:
- Personal or family history of germ cell tumor
- Cryptorchidism (RR 3.18 for cancer; RR 6.33 ipsilateral) 1
- History of orchidopexy
- Testicular atrophy (<12 mL volume) 3, 4
- Hypospadias (RR 2.41) 1
- Klinefelter syndrome 3
- Contralateral testicular cancer 3
If TML Found with Concurrent Testicular Mass:
- Urgent referral to specialist center 3
- Proceed with standard testicular tumor workup (tumor markers, radical inguinal orchiectomy)
Important Clinical Pitfalls
Common mistake: Ordering routine surveillance ultrasounds for isolated TML discovered incidentally. This leads to unnecessary healthcare costs, patient anxiety, and does not improve outcomes, as the cancer risk is equivalent to the general population 1.
Racial considerations: TML prevalence varies significantly by race (14.1% in Black men vs. 4% in White men) 2, but this does not change management—isolated TML remains benign regardless of ethnicity.
Bilateral vs. unilateral: While bilateral TML is more common, this distinction does not alter management in the absence of other risk factors 3, 5.
Rationale Behind Current Guidelines
The 2022 ACR guidelines 1 represent the highest quality, most recent evidence and explicitly state that TML "in the absence of a solid mass or other risk factors for GCTT does not confer an increased risk of malignant neoplasm." This recommendation prioritizes avoiding unnecessary interventions that could harm quality of life through anxiety, radiation exposure from follow-up imaging, and healthcare costs—without improving mortality or morbidity outcomes.
The ESUR guidelines 3 concordantly recommend against follow-up for isolated TML, reserving annual surveillance only for patients with established independent risk factors for testicular cancer.